CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -7.1% ·
aandelenstroom -0.7% ·
netto nieuwe posities -7.7%
— formule
Brede distributie — dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 128 | +7 | 95.71M | $8.15B | +10 | −2 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | — | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | — |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | — | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | — |
| Q2 2024 | 11 | — | 17.42M | $943.61M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passief) | 6.17M | — | $290.11M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passief) | 2.84M | -0.2% | $133.69M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passief) | 2.84M | -0.2% | $133.69M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 2.63M | -17.1% | $123.48M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 2.63M | -17.1% | $123.48M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 2.15M | +14.9% | $101.29M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 15 | Marshall Wace ✦ | 2.15M | +14.9% | $101.29M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 16 | Marshall Wace ✦ | 2.15M | +14.9% | $101.29M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 1.37M | +46.4% | $64.52M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 1.37M | +46.4% | $64.52M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 19 | Norges Bank ✦ (passief) | 989.72K | -0.3% | $46.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 616.49K | +13.7% | $29.00M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 21 | Renaissance Technologies ✦ | 192.17K | -21.4% | $9.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Point72 Asset Management ✦ | 169.91K | -63.4% | $7.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 91.17K | -64.8% | $4.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Millennium Management ✦ | 50.52K | -16.6% | $2.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 33.25K | -11.0% | $1.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 33.25K | -11.0% | $1.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 33.25K | -11.0% | $1.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| D. E. Shaw & Co. | $622,512 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 437 houders, 145.17M aandelen, $8.22B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 3.50K aand · $265,370
Officer, Director · 7.50K aand · $575,700
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie